Trial Profile
Phase I Trial of Weekly MEDI-522 in Patients With Refractory Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Etaracizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors MedImmune
- 28 Jan 2009 Actual end date (Jun 2002) added as reported by ClinicalTrials.gov.
- 28 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Oct 2006 New trial record.